Investors & Media

Feb 28, 2021 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Feb 28, 2021 / Feb 28, 2021 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News

2/25/21

BELLUS Health Reports Year 2020 Financial Results and Business Highlights
- Initiated the Phase 2b SOOTHE clinical trial in refractory chronic cough; topline results expected Q4 2021 with an interim analysis expected in mid-2021 - - Initiated the Phase 2 BLUEPRINT clinical trial in chronic pruritus associated with atopic dermatitis; topline results expected Q4 2021 - -...
Read More
2/22/21

BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
LAVAL, Quebec --(BUSINESS WIRE)--Feb. 22, 2021-- BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced...
Read More
1/14/21

BELLUS Health to Present at the Eleventh International Virtual Cough Symposium
LAVAL, Quebec --(BUSINESS WIRE)--Jan. 14, 2021-- BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today...
Read More